Review
Methotrexate use in rheumatoid arthritis. A clinician's perspective

https://doi.org/10.1016/S0162-3109(00)00184-3Get rights and content

Abstract

Aminopterine, a precursor of methotrexate (MTX), was first used for the treatment of rheumatoid arthritis (RA) in 1951 [Gubner, R., 1951. Therapeutic suppression of tissue reactivity: I. Comparison of the effects of cortisone and aminopterin. Am. J. Med. Sci. 221, 169–175; Gubner, R., August, S., Ginsberg, V., 1951. Therapeutic suppression of tissue reactivity: II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am. J. Med. Sci. 221, 176–182.]. Corticosteroids, and to some extent cyclophosphamide, took MTX out of the rheumatologist's armamentarium until the late 1970s–early 1980s when the toxic profile of these compounds became apparent. By the mid 1980s, four randomized clinical trials (RCTs) had proven beyond doubt the beneficial effects of MTX when administered to patients with established disease who had failed to respond to other compounds such as gold salts and d-penicillamine [Thompson, R.N., Watts, C., Edelman, J., Esdaile, J., and Russell, A.S., 1984. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J. Rheumatol. 11, 760–763; Andersen, P.A., West, S.G., O'Dell, J.R., Via, C.S., Claypool, R.G., and Kotzin, B.L., 1985. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann. Intern. Med. 103, 489–496; Weinblatt, M.E., Coblyn, J.S., Fox, D.A., Fraser, P.A., Holdsworth, D.E., Glass, D.N., and Trentham, D.E., 1985. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312, 818–822; Williams, H.J., Willkens, R.F., Samuelson, C.O.J., Alarcón, G.S., Guttadauria, M., Yarboro, C., Polisson, R.P., Weiner, S.R., Luggen, M.E., Billingsley, L.M., Dahl, S.L., Egger, M.J., Reading, J.C., and Ward, J.R., 1985. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 28, 721–730.]. Subsequently, these four trials were included in a meta-analysis and the drug was approved by the Food and Drug Administration for use in RA [Health and Public Policy Committee, H.P.P.C. and American College Physicians, A.C.P., 1987. Methotrexate in rheumatoid arthritis. Ann. Intern. Med. 107, 418–419; Paulus, H.E., 1986. FDA Arthritis Advisory Committee meeting: Methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma. Arthritis Rheum. 29, 1289–1290; Tugwell, P., Bennett, K., and Gent, M., 1987. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann. Intern. Med. 107, 358–366.]. Since then, rheumatologists have become aware of what Pincus et al. have called “the side effects” of RA comparing the morbidity and mortality caused by RA with that potentially caused by medications used to treat this disease [Pincus, T. and Callahan, L.F., 1993. The “side effects” of rheumatoid arthritis: joint destruction, disability and early mortality. Br. J. Rheumatol. 32, 28–37.]. Thus, during the 1990s the use of MTX for the treatment of RA became generalized [O'Dell, J.R., 1997. Methotrexate use in rheumatoid arthritis. Rheum. Dis. Clin. N Am. 23, 779–796 (a); Bannwarth, B., Vernhes, J., Schaeverbeke, T., and Dehais, J., 1995. The facts about methotrexate in rheumatoid arthritis. Rev. Rhum. 62, 471–473 (b); Bologna, C., Jorgensen, C., and Sany, J., 1997a. Methotrexate as the initial second-line disease modifying agent in the treatment of rheumatoid arthritis patients. Clin. Exp. Rheumatol. 15, 597–601; Bologna, C., Viu, P., Picot, M.C., Jorgensen, C., and Sany, J., 1997b. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate an open, retrospective, observational study. Br. J. Rheumatol. 36, 535–540.]. By now, basic and clinical investigators have gathered a wealth of information covering many aspects related to this compound, ranging from its mechanism of action to how it can be administered in a much safer way to patients.

This article highlights the way in which MTX is currently used by rheumatologists for the treatment of RA primarily, and to a lesser extent for the treatment of other rheumatic disorders. Other aspects of this compound have been covered elsewhere and will not be emphasized in this review.

Section snippets

Efficacy

Regardless of what is the preferred name for compounds such as methotrexate (MTX) (disease modifying anti-rheumatic drugs (DMARDs), second-line agents or slow-acting anti-rheumatic drugs), MTX is an anti-folate which has proven to be efficacious for the treatment of rheumatoid arthritis (RA), as demonstrated by the initial four randomized clinical trials (RCTs) included in Tugwell's meta-analysis as well as in publications reporting on cohorts of patients followed for months and even years. In

Toxicity

Early in the 1980s, toxicity was recognized as the major factor limiting the use of this compound Gispen et al., 1987, Alarcón et al., 1989. It was also recognized that some of the toxic manifestations, especially those occurring immediately after MTX administration (such as abdominal discomfort, alopecia, oral ulcerations and cytopenias), resembled complicated folate-deficiency resulting from the inhibition of dihydrofolic acid reductase (Baggott et al., 1993); the possibility that the

Doses, route and monitoring

MTX is administered weekly in a single oral dose or divided in two doses taken 12 h apart American College of Rheumatology AD HOC Committee in Clinical Guidelines, 1996, Alarcón, 1997. Folic acid can be safely administered prior to the initiation of MTX and while baseline hematological and chemical profiles are being obtained American College of Rheumatology AD HOC Committee in Clinical Guidelines, 1996, Alarcón, 1997. B12 levels and hepatitis serologies are also indicated. A chest radiograph

Methotrexate in other inflammatory disorders

The list of conditions for which MTX has been utilized is vast and includes diseases affecting different organ systems treated by a number of different specialists. Pulmonologists have used it for the treatment of severe sarcoidosis Lower and Baughman, 1990, Toews and Lynch, 1990, and asthma (Mullarkey et al., 1988); gastroenterologists for inflammatory bowel disorder and idiopathic granulomotous hepatitis Kozarek et al., 1989, Feagan et al., 1995, Knox et al., 1995; dermatologists for

Acknowledgements

To Ella Henderson for her most expert assistance in the preparation of this manuscript.

References (170)

  • R.D. Kozlowski et al.

    Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease

    Am. J. Med.

    (1990)
  • E.E. Lower et al.

    The use of low dose methotrexate in refractory sarcoidosis

    Am. J. Med. Sci.

    (1990)
  • S.K. Mackinnon et al.

    Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis

    Sem. Arthritis Rheum.

    (1985)
  • M. Abu-Shakra et al.

    Long term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome

    J. Rheumatol.

    (1995)
  • M. Abu-Shakra et al.

    Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy

    J. Rheumatol.

    (1994)
  • R. Aglas et al.

    Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis

    Arthritis Rheum.

    (1995)
  • M.J. Ahern et al.

    Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings

    Ann. Int. Med.

    (1991)
  • A. Al-Awadhi et al.

    Pancytopenia associated with low dose methotrexate therapy

    J. Rheumatol.

    (1993)
  • G.S. Alarcón

    Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders

  • G.S. Alarcón et al.

    Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group

    Ann. Intern. Med.

    (1997)
  • G.S. Alarcón et al.

    Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis

    J. Rheumatol.

    (1992)
  • G.S. Alarcón et al.

    Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

    Arthritis Rheum.

    (1989)
  • G.S. Alarcón et al.

    Survival and drug discontinuation analyses in a large cohort of methotrexate-treated rheumatoid arthritis patients

    Ann. Rheum. Dis.

    (1995)
  • Guidelines for monitoring drug therapy in rheumatoid arthritis

    Arthritis Rheum.

    (1996)
  • J. Aponte et al.

    Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate

    Arthritis Rheum.

    (1988)
  • J.M. Arias et al.

    Comparison of methods for identifying early methotrexate-induced hepatotoxicity in patients with rheumatoid arthritis

    J. Nucl. Med.

    (1993)
  • B. Aspe de la Iglesia et al.

    Pancitopenia e infecciones oportunistas en artritis reumatoid tratada con metotrexato

    Rev. Clin. Espanol

    (1990)
  • T.R. Bachman et al.

    Reversible lymphoma in rheumatoid arthitis patients treated with methotrexate: report of two cases

    Arthritis Rheum.

    (1996)
  • J.E. Baggott et al.

    Antifolates in rheumatoid arthritis: a hypothetical mechanism of action

    Clin. Exp. Rheumatol.

    (1993)
  • B. Bannwarth et al.

    The facts about methotrexate in rheumatoid arthritis

    Rev. Rheum.

    (1995)
  • K.S. Basin et al.

    Severe pancytopenia in a patient taking low dose methotrexate and probenecid

    J. Rheumatol.

    (1991)
  • S.R. Bergquist et al.

    The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate

    Arthritis Rheum.

    (1995)
  • J. Berthelot et al.

    Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths)

    Rev. Rheum.

    (1995)
  • D.J. Bjorkman et al.

    The effect of long-term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis

    Arthritis Rheum.

    (1993)
  • D.J. Bjorkman et al.

    Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis

    Arthritis Rheum.

    (1988)
  • W.D.J. Blackburn et al.

    Impotence in three rheumatoid arthritis patients treated with methotrexate

    Arthritis Rheum.

    (1989)
  • C. Bologna et al.

    Methotrexate as the initial second-line disease modifying agent in the treatment of rheumatoid arthritis patients

    Clin. Exp. Rheumatol.

    (1997)
  • C. Bologna et al.

    Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate an open, retrospective, observational study

    Br. J. Rheumatol.

    (1997)
  • S.L.J. Bridges et al.

    Methotrexate-induced liver abnormalities in rheumatoid arthritis

    J. Rheumatol.

    (1989)
  • S.L.J. Bridges et al.

    Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?

    J. Rheumatol.

    (1991)
  • M.A. Brown et al.

    Pancytopenia after accidental overdose of methotrexate. A complication of low-dose therapy for rheumatoid arthritis

    Med. J. Aust.

    (1991)
  • G.A. Bruyn et al.

    Fatal cardiac nodules in a patient with rheumatoid arthritis treated with low dose methotrexate

    J. Rheumatol.

    (1993)
  • R. Buchbinder et al.

    Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice

    J. Rheumatol.

    (1993)
  • L.M. Buckley et al.

    Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother

    Arthritis Rheum.

    (1997)
  • L.M. Buckley et al.

    Effect of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis

    J. Rheumatol.

    (1997)
  • M.T. Carpenter et al.

    Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy

    Orthopedics

    (1996)
  • G.J. Carroll et al.

    Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate

    J. Rheumatol.

    (1994)
  • J.M. Cash et al.

    Massive intrahepatic hemorrhage following routine liver biopsy in a patient with rheumatoid arthritis treated with methotrexate

    J. Rheumatol.

    (1992)
  • D.W. Ching

    Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate

    Ann. Rheum. Dis.

    (1995)
  • D.O. Clegg et al.

    Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis

    J. Rheumatol.

    (1989)
  • Cited by (0)

    View full text